ArticlePaediatric drugs2025

Vedolizumab Versus Other Biologics and the Risk of Venous Thromboembolism in Patients with Pediatric-Onset Inflammatory Bowel Diseases: A Target Trial Emulation Study.

Serena Yun-Chen Tsai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.